MGRX — Mangoceuticals, Inc. Common Stock

Mangoceuticals, Inc. Common Stock (MGRX) is a health information services company listed on NASDAQ. It is led by Jacob D. Cohen, based in 15110 N. Dallas Parkway, Dallas, TX, United States, 75248, with about 3 employees. Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. The company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Latest reported MGRX revenue for 2025-09-30 was $84.2K. Net income was -$7.6M. Revenue was down 49.9% from 2025-06-30 to 2025-09-30. MGRX currently screens at market cap $16.3M.

Use this MGRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MGRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MGRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Mangoceuticals, Inc. Common Stock even when a live quote feed is slow.